Amifostine protects rat kidneys during peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate
- 5 December 2006
- journal article
- research article
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 34 (5) , 763-771
Abstract
In peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues, the kidneys are the major dose-limiting organs, because of tubular reabsorption and retention of radioactivity. Preventing renal uptake or toxicity will allow for higher tumour radiation doses. We tested the cytoprotective drug amifostine, which selectively protects healthy tissue during chemo- and radiotherapy, for its renoprotective capacities after PRRT with high-dose [177Lu-DOTA0,Tyr3]octreotate.Keywords
This publication has 36 references indexed in Scilit:
- Survival and Response After Peptide Receptor Radionuclide Therapy With [90Y-DOTA0,Tyr3]Octreotide in Patients With Advanced Gastroenteropancreatic Neuroendocrine TumorsSeminars in Nuclear Medicine, 2006
- Radiolabeled Somatostatin Analog [177Lu-DOTA0,Tyr3]Octreotate in Patients With Endocrine Gastroenteropancreatic TumorsJournal of Clinical Oncology, 2005
- Time dependent protection of amifostine from renal and hematopoietic cisplatin induced toxicityLife Sciences, 2005
- Metabolic effects of amino acid solutions infused for renal protection during therapy with radiolabelled somatostatin analoguesNephrology Dialysis Transplantation, 2004
- Quality of Life in Patients With Gastroenteropancreatic Tumors Treated With [177Lu-DOTA0,Tyr3]octreotateJournal of Clinical Oncology, 2004
- Radiation nephropathySeminars in Nephrology, 2003
- Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancerSeminars in Oncology, 2002
- Improved tolerability of amifostine with rapid infusion and optimal patient preparationSeminars in Oncology, 2002
- Phase II trial of subcutaneous amifostine in patients undergoing radiation therapy for head and neck cancerSeminars in Oncology, 2002
- AmifostineDrugs, 2001